158 related articles for article (PubMed ID: 2153212)
1. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
3. Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist.
Chang RS; Lotti VJ; Chen TB; Keegan ME
Neurosci Lett; 1986 Dec; 72(2):211-4. PubMed ID: 3027627
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
[TBL] [Abstract][Full Text] [Related]
5. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of [3H][3-MeHis2]thyrotropin releasing hormone recognition sites in the rat brain by tifluadom, a kappa opiate receptor agonist.
Das S; Bhargava HN
Neuropharmacology; 1987 Aug; 26(8):1141-6. PubMed ID: 2889163
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
8. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
[TBL] [Abstract][Full Text] [Related]
9. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide.
Slaninova J; Knapp RJ; Wu JJ; Fang SN; Kramer T; Burks TF; Hruby VJ; Yamamura HI
Eur J Pharmacol; 1991 Jul; 200(1):195-8. PubMed ID: 1663041
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
Chang RS; Lotti VJ
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.
Anzini M; Canullo L; Braile C; Cappelli A; Gallelli A; Vomero S; Menziani MC; De Benedetti PG; Rizzo M; Collina S; Azzolina O; Sbacchi M; Ghelardini C; Galeotti N
J Med Chem; 2003 Aug; 46(18):3853-64. PubMed ID: 12930147
[TBL] [Abstract][Full Text] [Related]
12. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
[TBL] [Abstract][Full Text] [Related]
13. Novel glutamic acid derived cholecystokinin receptor ligands.
Freidinger RM; Whitter WL; Gould NP; Holloway MK; Chang RS; Lotti VJ
J Med Chem; 1990 Feb; 33(2):591-5. PubMed ID: 2299627
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors.
Rodriguez M; Amblard M; Galas MC; Lignon MF; Aumelas A; Martinez J
Int J Pept Protein Res; 1990 May; 35(5):441-51. PubMed ID: 2376470
[TBL] [Abstract][Full Text] [Related]
15. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
16. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
[TBL] [Abstract][Full Text] [Related]
17. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
Zhou W; Povoski SP; Bell RH
J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
[TBL] [Abstract][Full Text] [Related]
19. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
[TBL] [Abstract][Full Text] [Related]
20. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
Tabuchi S; Nakanishi I; Satoh Y
Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
